Baoqing Chen

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China · ORCID：0000-0001-9807-7425

发表论文 99 篇 · 总被引 1902 次 · h-index 21

代表论文

• Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial (2025 · The Lancet Oncology · 被引 10)
• RNF217-KEAP1-NRF2 feedback loop confers therapeutic resistance by inhibiting ferroptosis in esophageal squamous cell carcinoma (2025 · Drug Resistance Updates · 被引 6)
• Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002) (2026 · Journal of Clinical Oncology · 被引 5)
• Integrating lymphovascular invasion and ypTNM staging system for esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy and surgery: a multi-institutional analysis (2025 · British Journal of Cancer · 被引 1)
• Pan-immune-inflammation value predicts survival of patients with oesophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: a pooled analysis of two phase II trials (2025 · Annals of Medicine · 被引 1)
• Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002” (2026 · Journal of Clinical Oncology)